Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Bernd Seizinger
AddedMar 31, 2024
UpdatedMay 31, 2026
Bernd Seizinger

Bernd Seizinger

Board Member, Aprea Therapeutics

CrunchbaseLinkedIn

Bernd Seizinger's Career

Aprea Therapeutics
Aprea Therapeutics

Boston, MA, US

Board Member· Board
CryptoMedix
CryptoMedix

Harpswell, ME, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Bernd Seizinger's Career

Aprea Therapeutics
Aprea Therapeutics
Acquired02019Boston, MA, US
Board Member· Board

Leadership at Aprea Therapeutics

Oren GiladOren GiladFounder
Jack HennemanJack HennemanBoard Member
Chris SchadeChris SchadeBoard Member

Similar to Aprea Therapeutics

ApoGen BiotechnologiesApoGen BiotechnologiesSeattle, WA, USTherapeuticsest. 2014ApoGen BiotechnologiesSeattle, WA, US · est. 2014

ApoGen Biotechnologies, Inc.: Innovating new class of therapeutics in biotechnology.

Series A · $11M7
Apexian PharmaceuticalsApexian PharmaceuticalsIndianapolis, IN, USDrugs, Pharmaceuticalsest. 2005Apexian PharmaceuticalsIndianapolis, IN, US · est. 2005

Apex Therapeutics, based in Indianapolis, US, develops and markets drugs for cancer and eye diseases.

Angel · $6.9M5
Atossa TherapeuticsAtossa TherapeuticsSeattle, WA, USTherapeuticsest. 2009Atossa TherapeuticsSeattle, WA, US · est. 2009

Seattle-based Atossa Therapeutics, Inc. pioneers in discovering unique therapeutics for breast cancer globally.

Public · $57.8M75
Parthenon TherapeuticsParthenon TherapeuticsCambridge, MA, USCancer Therapiesest. 2019Parthenon TherapeuticsCambridge, MA, US · est. 2019

Parthenon Therapeutics develops innovative anti-cancer therapies, reprogramming the tumor microenvironment.

Series A · $65M43
CryptoMedix
CryptoMedix
Angel$276.5k302013Harpswell, ME, US
Board Member· Board

Leadership at CryptoMedix

Peter BrooksPeter BrooksCo-Founder
Leonard LiebesLeonard LiebesCo-Founder

Similar to CryptoMedix

Meditope BiosciencesMeditope BiosciencesPasadena, CA, USCancer Therapeuticsest. 2011Meditope BiosciencesPasadena, CA, US · est. 2011

Meditope Biosciences: Biotech firm specializing in antibody-based cancer treatments.

Series A · $3.6M6
CybrexaCybrexaNew Haven, CT, USOncology, Therapeuticsest. 2017CybrexaNew Haven, CT, US · est. 2017

Cybrexa Therapeutics: A clinical-stage biotech firm, innovating in oncology with DNA repair inhibitors.

Series B · $44.4M38
Camino PharmaCamino PharmaSan Diego, CA, USCancer Treatment, Drug Developmentest. 2014Camino PharmaSan Diego, CA, US · est. 2014

Camino Pharma: A tech startup pioneering first-in-class cancer and CNS disorder therapies.

Seed · $13.7M3
IntellimedixIntellimedixAtlanta, GA, USDisease Treatmentsest. 2012IntellimedixAtlanta, GA, US · est. 2012

Intellimedix: Pioneering biotech firm accelerating discovery and development of disease treatments.

Seed · $2.3M30

Bernd Seizinger's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Bernd Seizinger

Jeff McLarenJeff McLarenBoard Member · HealthStreamMike KijewskiMike KijewskiFounder · Gamma BasicsRon LevyRon LevyBoard Member · The Crypto CompanyDavid R EpsteinDavid R EpsteinBoard Member · Valo Health